Royal Bank of Canada Cuts Apellis Pharmaceuticals (NASDAQ:APLS) Price Target to $18.00
Apellis Pharmaceuticals (NASDAQ:APLS – Free Report) had its target price cut by Royal Bank of Canada from $21.00 to $18.00 in a research report report published on Thursday,Benzinga reports. They currently have a sector perform rating on the stock. Other analysts have also recently issued research reports about the stock. Wells Fargo & Company decreased […]
Apellis Pharmaceuticals (NASDAQ:APLS – Free Report) had its target price cut by Royal Bank of Canada from $21.00 to $18.00 in a research report report published on Thursday,Benzinga reports. They currently have a sector perform rating on the stock. Other analysts have also recently issued research reports about the stock. Wells Fargo & Company decreased […]
